bluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE) in a report released on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Several other equities research analysts have also recently weighed in on BLUE. Cantor Fitzgerald restated a “neutral” rating on shares of bluebird bio in a research note on Monday, September 16th. Bank of America dropped their price target on bluebird bio from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th. Wells Fargo & Company lowered their price objective on shares of bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Wednesday, September 25th. Robert W. Baird lowered their price objective on bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a report on Thursday, August 15th. Finally, Barclays reduced their target price on bluebird bio from $8.00 to $4.00 and set an “overweight” rating for the company in a report on Thursday, August 15th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $4.63.

bluebird bio Price Performance

bluebird bio stock opened at $0.47 on Friday. The business’s 50-day moving average price is $0.53 and its 200 day moving average price is $0.83. The company has a quick ratio of 0.57, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. The firm has a market cap of $90.36 million, a price-to-earnings ratio of -0.21 and a beta of 0.75. bluebird bio has a 52 week low of $0.45 and a 52 week high of $5.53.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. The firm had revenue of $18.57 million for the quarter. bluebird bio had a negative net margin of 567.29% and a negative return on equity of 207.25%. As a group, sell-side analysts anticipate that bluebird bio will post -1.41 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allegheny Financial Group LTD bought a new position in bluebird bio in the second quarter valued at $25,000. Sequoia Financial Advisors LLC increased its stake in shares of bluebird bio by 48.0% in the 1st quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 13,000 shares in the last quarter. Bayesian Capital Management LP bought a new position in bluebird bio in the 1st quarter worth $52,000. SG Americas Securities LLC boosted its position in shares of bluebird bio by 152.4% in the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 74,185 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in bluebird bio by 113.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 29,113 shares in the last quarter. 87.43% of the stock is owned by institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.